Abstract Number: 2845 • 2013 ACR/ARHP Annual Meeting
“Work It” Recruitment: Lessons Learned From An Arthritis Work Disability Prevention Randomized Trial
Background/Purpose: Participant recruitment is a critical component of randomized controlled trials, particularly large ones with long term outcomes like work disability. Recruitment needs to be…Abstract Number: 2846 • 2013 ACR/ARHP Annual Meeting
Baseline Work Participation Of a Novel Intervention To Prevent Work Disability Among Persons With Arthritis: The “Work it” Study
Background/Purpose: People with arthritis are at risk of work disability. Job accommodation and educational programs delivered before imminent work loss can minimize work disability, yet…Abstract Number: 2847 • 2013 ACR/ARHP Annual Meeting
The Employment Experience Of People With Arthritis: Findings From An On-Line Survey
Background/Purpose: Understanding the employment experience and needs of people with arthritis is growing in importance as baby boomers make up an increasing proportion of the…Abstract Number: 2848 • 2013 ACR/ARHP Annual Meeting
A Randomised Controlled Trial (RCT) of Telephone Delivered Cognitive Behaviour Therapy (tCBT) and Exercise In The Management Of Chronic Widespread Pain (CWP): Identifying Long-Term Outcome and Who Benefits From Which Treatment
Background/Purpose: CWP is challenging for rheumatologists to manage and results from long-term epidemiological studies demonstrate that improvement in symptoms is uncommon. Recent reviews have, however, suggested…Abstract Number: 2849 • 2013 ACR/ARHP Annual Meeting
Medication Adherence and Healthcare Costs Among Patients With Fibromyalgia: Combination Medication Versus Duloxetine, Pregabalin, and Milnacipran Initiators
Background/Purpose: The combined use of prescription drugs (Rx) with complementary mechanisms of action has been described for treating fibromyalgia (FM). We examined medication adherence and…Abstract Number: 2850 • 2013 ACR/ARHP Annual Meeting
Once Daily Controlled-Release Pregabalin In Fibromyalgia Patients: A Phase 3 Double-Blind, Randomized Withdrawal, Placebo-Controlled Study
Background/Purpose: Pregabalin (PGB) is currently approved for the treatment of fibromyalgia (FM) for twice daily dosing over a range of 300-450 mg/day. A pregabalin controlled-release…Abstract Number: 2851 • 2013 ACR/ARHP Annual Meeting
The Polysymptomatic Distress Scale As a Measure Of Disease and Practice Severity In Fibromyalgia
Background/Purpose: The 2010 American College of Rheumatology (ACR) fibromyalgia (FM) criteria created a scale for the measurement of severity of pain extent—the 0-19 Widespread Pain…Abstract Number: 2852 • 2013 ACR/ARHP Annual Meeting
Real-Life Assessment Of The Validity Of Patient Global Impression Of Change In Fibromyalgia
Background/Purpose: Assessing fibromyalgia (FM) is challenging due to the lack of hard outcomes and the need to rely on patient-reported symptoms. Completion of questionnaires by…Abstract Number: 2854 • 2013 ACR/ARHP Annual Meeting
Restricting Back Pain and Subsequent Mobility Disability In Community-Living Older Persons
Background/Purpose: Although back pain is common and costly, few longitudinal studies have evaluated the association between back pain, severe enough to restrict activity (hereafter referred…Abstract Number: 2855 • 2013 ACR/ARHP Annual Meeting
Association Of Back Pain With Functional Limitations In Patients With Knee and Hip Osteoarthritis
Background/Purpose: Back pain, most commonly occurring in the lower back, is a prevalent condition and common reason for both decreased function and quality of life.…Abstract Number: 2856 • 2013 ACR/ARHP Annual Meeting
Influence Of Mechanical Symptoms On Treatment Outcomes For Meniscal Tear In The Setting Of Osteoarthritis
Background/Purpose: Clinicians are challenged to identify those patients with knee pain, osteoarthritis (OA) and imaging evidence of a meniscal tear (MT) who are likely to…Abstract Number: 2857 • 2013 ACR/ARHP Annual Meeting
The Role Of FAM173b As a Newly Identified Regulator Of Chronic Pain
Background/Purpose: Chronic pain is a major debilitating problem in many inflammatory diseases including rheumatoid arthritis and osteoarthritis. Pain is an important problem during active disease…Abstract Number: 2816 • 2013 ACR/ARHP Annual Meeting
Pilot Phase Outcomes From The ACR/Carra Inter-Institutional Mentoring Program In Pediatric Rheumatology
Background/Purpose: In pediatric rheumatology, the small size of many academic programs translates into limited mentoring options for early career physicians. To address this “mentorship gap,”…Abstract Number: 2817 • 2013 ACR/ARHP Annual Meeting
Objective Assessment Of Musculoskeletal Physical Examination Skills During Continuing Education Programs For Primary Care Providers Adds Significant Information Not Obtained Through Self-Assessment
Background/Purpose: Self-assessment is the most frequently used method in the evaluation of continuing medical education (CME) programs. This multi-institutional project was designed to examine convergent validity…Abstract Number: 2819 • 2013 ACR/ARHP Annual Meeting
Administration Of a Multi-Epitope Citrullinated Peptide Attuneuates adjuvant Induced Arthritis In Rats Via Induction Of Immune Tolerance
Background/Purpose: Antigen-induced peripheral tolerance is a potentially efficient and specific therapeutic approach to attenuate autoimmunity. Citrullinated peptides are major targets of disease-specific autoantibodies in Rheumatoid…
ACR Meeting Abstracts